Development of renal disease in <font color="red">people_4</font> <font color="red">at_4</font> <font color="red">high_4</font> <font color="red">cardiovascular_4</font> <font color="red">risk_4</font> <font color="red">:_4</font> results of the HOPE randomized study . 
<br>
<br> In <font color="red">people_3</font> <font color="red">with_3</font> <font color="red">diabetes_3</font> <font color="red">,_3</font> renal disease tends to progress from microalbuminuria to clinical proteinuria to renal insufficiency . Little evidence has been published for the <font color="red">nondiabetic_2</font> <font color="red">population_2</font> <font color="red">._2</font> This study retrospectively analyzed changes of proteinuria over 4.5 yr in the <font color="red">HOPE_1</font> <font color="red">(_1</font> <font color="red">Heart_1</font> <font color="red">Outcomes_1</font> <font color="red">and_1</font> <font color="red">Prevention_1</font> <font color="red">Evaluation_1</font> <font color="red">)_1</font> <font color="red">study_1</font> <font color="red">,_1</font> which compared ramipril 's effects to placebo in <font color="red">9297_4</font> <font color="red">participants_4</font> <font color="red">,_4</font> <font color="red">including_3</font> <font color="red">3577_3</font> <font color="red">with_3</font> <font color="red">diabetes_3</font> <font color="red">and_3</font> <font color="red">1956_3</font> <font color="red">with_3</font> <font color="red">microalbuminuria_3</font> <font color="red">._3</font> <font color="red">This_1</font> <font color="red">report_1</font> <font color="red">is_1</font> <font color="red">restricted_2</font> <font color="red">to_2</font> <font color="red">7674_5</font> <font color="red">participants_5</font> <font color="red">with_4</font> <font color="red">albuminuria_4</font> <font color="red">data_4</font> <font color="red">at_4</font> <font color="red">baseline_4</font> <font color="red">and_4</font> <font color="red">at_4</font> <font color="red">follow_4</font> <font color="red">-_4</font> <font color="red">up_4</font> <font color="red">._4</font> <font color="red">Inclusion_1</font> <font color="red">criteria_1</font> <font color="red">were_1</font> <font color="red">known_1</font> <font color="red">vascular_1</font> <font color="red">disease_1</font> <font color="red">or_1</font> <font color="red">diabetes_1</font> <font color="red">plus_1</font> <font color="red">one_1</font> <font color="red">other_1</font> <font color="red">cardiovascular_1</font> <font color="red">risk_1</font> <font color="red">factor_1</font> <font color="red">,_1</font> <font color="red">exclusion_1</font> <font color="red">criteria_1</font> <font color="red">included_1</font> <font color="red">heart_1</font> <font color="red">failure_1</font> <font color="red">or_1</font> <font color="red">known_1</font> <font color="red">impaired_1</font> <font color="red">left_1</font> <font color="red">ventricular_1</font> <font color="red">function_1</font> <font color="red">,_1</font> <font color="red">dipstick_1</font> <font color="red">-_1</font> <font color="red">positive_1</font> <font color="red">proteinuria_1</font> <font color="red">(_1</font> <font color="red">>_1</font> <font color="red">1_1</font> <font color="red">+_1</font> <font color="red">)_1</font> <font color="red">,_1</font> <font color="red">and_1</font> <font color="red">serum_1</font> <font color="red">creatinine_1</font> <font color="red">>_1</font> <font color="red">2.3_1</font> <font color="red">mg_1</font> <font color="red">/_1</font> <font color="red">dl_1</font> <font color="red">(_1</font> <font color="red">200_1</font> <font color="red">microM_1</font> <font color="red">)_1</font> <font color="red">._1</font> Baseline microalbuminuria predicted subsequent clinical proteinuria for the study participants overall ( adjusted odds ratio [ OR ] , 17.5 ; 95% confidence interval [ CI ] , 12.6 to 24.4 ) , in participants without diabetes ( OR , 16.7 ; 95% CI , 8.6 to 32.4 ) , and in participants with diabetes ( OR , 18.2 ; 95% CI , 12.4 to 26.7 ) . Any progression of albuminuria ( defined as new microalbuminuria or new clinical proteinuria ) occurred in 1859 participants ; 1542 developed new microalbuminuria , and 317 participants developed clinical proteinuria . Ramipril reduced the risk for any progression ( OR , 0.87 ; 95% CI , 0.78 to 0.97 ; P = 0.0146 ) . <font color="red">People_1</font> <font color="red">without_1</font> <font color="red">and_1</font> <font color="red">with_1</font> <font color="red">diabetes_1</font> who are at high risk for cardiovascular disease are also at risk for a progressive rise in albuminuria . Microalbuminuria itself predicts clinical proteinuria in <font color="red">nondiabetic_2</font> <font color="red">and_2</font> <font color="red">in_2</font> <font color="red">diabetic_3</font> <font color="red">people_3</font> <font color="red">._2</font> Ramipril prevents or delays the progression of albuminuria .